Cargando…

Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk

Multiple lines of evidence demonstrate that low-density lipoprotein-cholesterol causes atherosclerotic cardiovascular disease. Thus, targeting and lowering low-density lipoprotein-cholesterol is the principal strategy to reduce cardiovascular disease risk in primary and secondary prevention. Statin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rikhi, Rishi, Shapiro, Michael D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369522/ https://www.ncbi.nlm.nih.gov/pubmed/35956226 http://dx.doi.org/10.3390/jcm11154611

Ejemplares similares

Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI
por: Vallejo-Vaz, Antonio J., et al.
Publicado: (2022)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions
por: Mendez, Keegan, et al.
Publicado: (2022)

A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD
por: Srivastava, Rai Ajit K.
Publicado: (2023)

Gauging ASCVD Risk, Does Race Matter?
por: Zuo, Ming-Liang, et al.
Publicado: (2022)

Association of hyperuricemia combined with sarcopenia on ASCVD risk
por: Nie, Guqiao, et al.
Publicado: (2023)

Highlights in ASCVD Primary Prevention for 2021
por: Polonsky, Tamar S., et al.
Publicado: (2022)

Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk
por: Katzmann, Julius L., et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
por: Rikhi, Rishi, et al.
Publicado: (2023)

Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors
por: Dansinger, Michael L., et al.
Publicado: (2019)

The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers
por: Choi, Seonghoon
Publicado: (2019)

Health Literacy is Essential to ASCVD Prevention in Youth
por: Mann, Harnoor K., et al.
Publicado: (2023)

IMPACT OF THE COVID-19 PANDEMIC ON THE MANAGEMENT OF RISK FACTORS IN PATIENTS WITH ASCVD
por: Karalis, Dean, et al.
Publicado: (2023)

Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl
por: Robinson, Jennifer G., et al.
Publicado: (2020)

RELATION OF 10-YEAR ASCVD RISK SCORE WITH SEVERE COVID-19 OUTCOMES
por: Arif, Yousif, et al.
Publicado: (2022)

LDL-C: lower is better for longer—even at low risk
por: Penson, Peter E., et al.
Publicado: (2020)

Newer agents in antiplatelet therapy: a review
por: Yeung, Jennifer, et al.
Publicado: (2012)

Newer agents for Helicobacter pylori eradication
por: Fiorini, Giulia, et al.
Publicado: (2012)

Value of Newer Therapeutic Agents in Leukaemia
por: Hayhoe, F. G. J.
Publicado: (1969)

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents
por: Kannarkat, George T., et al.
Publicado: (2022)

Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition
por: Li, Qiaowei, et al.
Publicado: (2020)

Comparison of Framingham Cardiovascular Risk Criteria and ASCVD Score in Iranian Obese Patients
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2023)

Metabolomics profile and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
por: Dehghanbanadaki, Hojat, et al.
Publicado: (2023)

Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid
por: Mascarenhas-Melo, Filipa, et al.
Publicado: (2013)

COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD
por: Myers, Kelly D., et al.
Publicado: (2021)

External validation of the ACC/AHA ASCVD risk score in a Colombian population cohort
por: Rodríguez-Ariza, Carlos Daniel, et al.
Publicado: (2023)

Newer Hemostatic Agents Used in the Practice of Dermatologic Surgery
por: Henley, Jill, et al.
Publicado: (2013)

Identifying Opportunities for Impact of Community-Based Pharmacist-Led Biometric Health Screenings on ASCVD Risk
por: Newell, Bradley J., et al.
Publicado: (2023)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population
por: Xu, Xiaoyi, et al.
Publicado: (2023)

Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering
por: Sun, Peng, et al.
Publicado: (2021)

10-year ASCVD risk is positively correlated with depressive symptoms in a large general population
por: Sun, Guo-Zhe, et al.
Publicado: (2019)

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals
por: Enas, Enas A., et al.
Publicado: (2020)

Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
por: Stoll, Felicitas, et al.
Publicado: (2022)

Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy
por: Sciattella, Paolo, et al.
Publicado: (2021)

Beyond LDL: Understanding Triglyceride-Rich Lipoproteins to Tackle Residual Risk
por: Gugliucci, Alejandro
Publicado: (2023)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
por: Zhang, Lei, et al.
Publicado: (2019)

Analisi di costo-utilità di evolocumab in pazienti con ASCVD in Italia
por: Marcellusi, Andrea, et al.
Publicado: (2021)

Newer Oral Anticoagulant Agents: A New Era in Medicine
por: Goel, Ramil, et al.
Publicado: (2012)

Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria
por: Taneja, Neelam, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6ir9augfu30qg7ag20ik72l8pf